HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors

September 19, 2026 updated by: Parr Biotechnology (Hebei) Co., Ltd.

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Intratumoral Injection of HP007 Injection as Monotherapy in Patients With Relapsed or Refractory Advanced Solid Tumors, and to Explore the Preliminary Efficacy of HP007

This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of HP007 monotherapy in patients with advanced malignant solid tumors.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

44

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Jilin
      • Changchun, Jilin, China, 130000
        • Recruiting
        • The First Hospital of Jilin University
        • Contact:
        • Principal Investigator:
          • Yanhua Ding, Chief Physician

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male/female, 18-75 years inclusive.
  • Histologically-confirmed unresectable advanced tumors (breast cancer, HNSCC, cutaneous melanoma, prostate cancer, HCC, etc.);
  • no effective standard therapy or disease relapse/metastasis post-standard-of-care.
  • ECOG PS 0-1;
  • expected survival ≥3 months.
  • At least 1 measurable lesion by RECIST 1.1. Lesion in prior radiation field must have confirmed progression ≥4 weeks post-radiation. Prostate cancer subjects must meet PCWG3 progression criteria.
  • At least one lesion suitable for repeated intratumoral injection.
  • Adequate hematopoietic and organ function:
  • Males and females of child-bearing potential agree effective contraception from ICF signature to 3 months after last dose.
  • Voluntarily sign ICF and comply with study procedures.

Exclusion Criteria:

  1. Past/current medical conditions

    • CNS or leptomeningeal metastasis.
    • Residual toxicity from prior anti-tumor therapy >Grade 1 (CTCAE 6.0), except alopecia and Grade 2 peripheral neuropathy without safety risk.
    • Poorly controlled pleural / ascitic / pericardial effusion requiring local intervention or repeated drainage.
    • Active autoimmune disease or high-risk history of recurrence; organ transplant with immunosuppression.
    • Interstitial lung disease / non-infectious pneumonitis; pulmonary embolism within prior 12 weeks.
    • Severe cardio-cerebrovascular events within 6 months; QTcF ≥470 msec; LVEF ≤50%; NYHA ≥III heart failure; history of long-QT syndrome or ongoing QTc-prolonging drugs.
    • Uncontrolled hypertension (SBP>160 mmHg and/or DBP>100 mmHg) or other uncontrolled systemic diseases.
    • High bleeding risk / coagulation disorders: inherited/acquired bleeding-thrombotic predisposition; major bleeding within 3 months; thrombolytics within 10 days; ongoing anticoagulant/antiplatelet therapy (except heparin for CVC patency).
    • Immunodeficiency; history of solid-organ or hematopoietic stem-cell transplantation.
    • Active TB within past 5 years.
    • Severe infection / trauma / GI perforation / fistula / tumor vascular invasion / bowel obstruction within 4 weeks; active infection or antibiotic use within prior 2 weeks (prophylaxis allowed); unexplained fever >38.5 ℃ (tumor-related fever may be allowed per Investigator judgment).
    • Other active malignancy within 3 years, except: cervical carcinoma in-situ, local basal-cell carcinoma, or malignancies cured ≥5 years without recurrence.
  2. Prior medications & treatments

    • Local radiotherapy completed <1 week before first dose; >30% bone-marrow / extensive-field radiotherapy completed <4 weeks before first dose.
    • Anti-tumor therapy within 4 weeks or less than 5 half-lives (whichever shorter).
    • Systemic corticosteroids (>10 mg prednisone equivalent/day) or other immunosuppressants within 14 days.
    • Prior immunotherapy with irAEs ≥Grade 3.
    • Prior systemic TLR-agonist treatment (topical TLR agonists e.g. imiquimod permitted).
    • Vaccination within 1 month prior to enrolment.
  3. Allergy, general status & others

    • Severe hypersensitivity (CTCAE 6.0 ≥Grade 3) to any investigational product component.
    • Active HBV / HCV, positive syphilis or HIV serology.
    • Participated in another interventional clinical trial within 4 weeks.
    • Major surgery within 4 weeks before screening or planned major surgery during study.
    • Alcohol / illicit-drug / substance abuse within 12 months.
    • Documented neurological/psychiatric disorders leading to poor compliance.
    • Pregnant or lactating females.
    • Subjects judged unsuitable by the Investigator for any other reason.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HP007

Participate will recepit HP007 monotherpy with 4 dose groups

Participate will recepit HP007 monotherpy with 4 dose groups

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
DLT
Time Frame: up to one year

Safety endpoints: incidence and severity of DLT

up to one year
AE
Time Frame: up to two years

Safety endpoints: incidence and severity of adverse events (AE); Abnormal changes in laboratory and other tests with clinical significance

up to two years
SAE
Time Frame: up to two years

Safety endpoints: incidence and severity of serious adverse events (SAE); Abnormal changes in laboratory and other tests with clinical significance

up to two years
MTD
Time Frame: up to one year

Maximum tolerated dose (MTD)

up to one year
RP2D
Time Frame: up to one year

Recommended dose for phase II trial

up to one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ORR
Time Frame: up to two years

Efficacy endpoints: Objective response rate (ORR) per RECIST v1.1 or mRecist 1.1 or PCWG3

up to two years
DOR
Time Frame: up to two years

Efficacy endpoints: Duration of response (DOR) per RECIST v1.1 or mRecist 1.1 or PCWG3

up to two years
DCR
Time Frame: up to two years

Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1 or mRecist 1.1 or PCWG3

up to two years
PFS
Time Frame: up to two years

Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1 or mRecist 1.1 or PCWG3

up to two years
OS
Time Frame: up to two years

Efficacy endpoints: Overall survival (OS)

up to two years
Peak concentration(Cmax)
Time Frame: up to two years

The pharmacokinetic parameters of WJ47156:peak concentration (Cmax)

up to two years
the time to receive Cmax(Tmax)
Time Frame: up to two years

The pharmacokinetic parameters of HP007:the time to receive Cmax (Tmax)

up to two years
Area Under the plasma concentration-time curve (AUC0-t, AUC0-∞)
Time Frame: up to two years

The pharmacokinetic parameters of HP007 :area under the plasma concentration-time curve (AUC0-t, AUC0-∞)

up to two years
Volume of distribution (Vd)
Time Frame: up to two years

The pharmacokinetic parameters of HP007 :Volume of distribution (Vd)

up to two years
Rate of clearance (C)
Time Frame: up to two years

The pharmacokinetic parameters of HP007 :Rate of clearance (CL)

up to two years
Terminal half-life (t1/2)
Time Frame: up to two years

The pharmacokinetic parameters of WJ47156 :terminal half-life (t1/2),

up to two years
Steady-state peak concentration(Cmax,ss)
Time Frame: up to two years

The pharmacokinetic parameters of HP007 :steady-state peak concentration(Cmax,ss) for the main PK parameters for multiple dose

up to two years
Plasma trough concentration at steady state(Cmin,ss)
Time Frame: up to two years

The pharmacokinetic parameters of HP007:Plasma trough concentration at steady state(Cmin,ss) for the main PK parameters for multiple dose

up to two years
Accumulation ratio for AUC
Time Frame: up to two years

The pharmacokinetic parameters of HP007:Accumulation ratio of area-under-the-curve, defined as steady-state AUC within one dosing interval divided by Day 1 AUC (typically AUC₀-₂₄h). It characterizes overall systemic exposure accumulation over the dosing cycle, used for efficacy and total exposure assessment.

up to two years
the time to receive Cmax at steady state(Tmax,ss)
Time Frame: up to two years

The pharmacokinetic parameters of HP007 :the time to receive Cmax at steady state(Tmax,ss)for the main PK parameters for multiple dose)

up to two years
Area Under the plasma concentration-time curve at steady state (AUC0-t, ss)
Time Frame: up to two years

The pharmacokinetic parameters of HP007:area under the plasma concentration-time curve at steady state (AUC0-t, ss)for the main PK parameters for multiple dose)

up to two years
ADA
Time Frame: up to two years

The incidence and changes of anti-drug antibody (ADA) after treatment were observed

up to two years
Nab
Time Frame: up to two years

The incidence and changes of neutralizing antibody (Nab) after treatment were observed

up to two years
Cytokines
Time Frame: up to one year

The changes of serum cytokines (IFN-α, IFN-γ, IL-6, IL-10, and chemokines IFN-γ-inducible protein 10 (IP-10) and TNF-α )in peripheral blood before and after treatment were observed

up to one year
Subtype of lymphocyte
Time Frame: up to one year

Flow cytometry was used to detect the changes in lymphocyte subsets in peripheral blood before and after treatment

up to one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 17, 2026

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2028

Study Registration Dates

First Submitted

August 26, 2026

First Submitted That Met QC Criteria

August 31, 2026

First Posted (Actual)

September 2, 2026

Study Record Updates

Last Update Posted (Actual)

September 23, 2026

Last Update Submitted That Met QC Criteria

September 19, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HP007CH101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.